原癌基因Gankyrin及其在肿瘤发生中的作用研究进展

doi:10.3969/j.issn.1004-616x.2015.01.016

摘要/Abstract

摘要：

肿瘤的发生和发展是多基因交互影响、多种环境因素协同作用的结果。Gankyrin是近年来发现的一种新的原癌基因，研究表明Gankyrin在正常肝组织到肝癌过程中表达逐渐增强，提示其可能影响了肝细胞癌的发生过程。后来研究又陆续发现Gankyrin蛋白在肺癌、乳腺癌、结直肠癌等多种肿瘤组织中高表达。Gankyrin在调控细胞周期进程、细胞凋亡以及细胞免疫等多种生物学事件中发挥重要作用，从而加速细胞恶性化程度，促进肿瘤的发生。本文主要综述Gankyrin的表达调控，参与肿瘤发生的分子机制以及在化学物致肝癌发生中的作用。

关键词: 肿瘤, Gankyrin, 分子机制, 肝癌

王灵巧，陈济安，舒为群. 原癌基因Gankyrin及其在肿瘤发生中的作用研究进展[J]. 癌变·畸变·突变, doi: 10.3969/j.issn.1004-616x.2015.01.016.

参考文献

[1] Aleksic K，Lackner C，Geigl JB，et al. Evolution of genomic instability in diethylnitrosamine-induced hepatocarcinogenesis in mice [J]. Hepatology，2011，53(3)：895-904.

[2] Higashitsuji H，Itoh K，Nagao T，et al. Reduced stability of retinoblastoma protein by Gankyrin，an oncogenic ankyrin-repeat protein overexpressed in hepatomas[J]. Nat Med，2000，6(1)： 96-99.

[3] Krogan NJ，Lam MH，Fillingham J，et al. Proteasome involvement in the repair of DNA double-strand breaks[J]. Mol Cell，2004，16(6)： 1027-1034．

[4] Lim IK. Specturm of molecular ehnages during hepatoeareinogenesis induced by DEN and other ehemiealsin Fisher344 male rats[J]. Mech Ageing Dev，2003，124(4)：697-708.

[5] Funakoshi M，Tomko RJ Jr，Kobayashi H，et al. Multiple assembly chaperones govern biogenesis of the proteasome regulatory particle base[J]. Cell，2009，29，137(5)：887-899.

[6] Roelofs J，Park S，Haas W，et al. Chaperone-mediated pathway of proteasome regulatory particle assembly[J]. Nature，2009，11，459 (7248)：861-865.

[7] Jin BF，He K，Wang HX，et al. Proteomies analysis reveals insight into the mechanism of H-Ras-mediated transformation[J]. Proteome Res，2006，5：2815- 2823.

[8] Her GM，Cheng CH，Hong JR，et al. Imbalance in liver homeostasis leading to hyperplasia by overexpressing either one of the Bcl-2-related genes，zfBLP1 and zfMcl-1a [J]. Dev Dyn，2006， 235(2)：515-523.

[9] Qian YW，Chen Y，Yang W，et al. p28GANK prevents degradation of Oct4 and promotes expansion of tumor-initiating cells in hepato-carcinogenesis[J]. Gastroenterology，2012，142(7)：1547-1558.

[10] Jiang YJ，Polina I，Jin JL，et al. FXR inhibits gankyrin in mouse livers and prevents development of liver cancer[J]. Hepatology，2013， 57(3)：1098-1106.

[11] Fu J，Chen Y，Cao J，et al. p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways[J]. Hepatology， 2011，53(1)：181-192.

[12] Man JH，Liang B，Gu YX，et al. Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells[J]. J Clin Invest，2010，120(8)：2829-2841.

[13] Li J，Tsai MD. Novel insights into the INK4-CDK4/6-Rb pathway： counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb[J]. Biochemistry，2002，41(12)： 3977-3983.

[14] Meng Yun，He Lijie，Guo Xuegang，et al. Gankyrin promotes the proliferation of human pancreatic cancer[J]. Cancer Letters，2010， (297)：9-17.

[15] Krzywda S，Brzozowski AM，Higashitsuji H，et al. The crystal structure of gankyrin，an oncoprotein found in complexes with cyclin-dependent kinase 4，a 19 S proteasomal ATPase regulator，and the tumor suppressors Rb and p53[J]. J Biol Chem，2004，279(2)：1541-1545.

[16] Higashitsuji H，Itoh K，Sakurai T，et al. The oncoprotein gankyrin binds to MDM2/HDM2，enhancing ubiquitylation and degradation of p53[J]. Cancer Cell，2005，8(1)：75-87.

[17] Polina，Lubov，Nikolai A. Intracellular signaling and hepatocelluar carcinoma[J]. Semin Cancer Biol，2011， 21(1)：28-34.

[18] Nagoa T，Higashitsuji H，Nonoguehi K，et al. MAGE-A4 interacts with the liver oneoprotein gaknyrin and suppresses its tumorigenic activity[J]. J Biol Chem，2003，278：10668-10674.

[19] Didonato JA，Hayakawa M，Rothwarf DM，et al. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB[J]. Nature，1997，388(6642)：548-554.

[20] Li Y，Lin W，Holger W，et al. Defective lymphotoxin-β receptor-induced NF-κB transcriptional activeity in NIK-deficient mice[J]. Science，2001，291 (5511)：2162-2165.

[21] Karin M，Greten FR. NF-κB：Linking inflammation and immunity to cancer development and progression[J]. Nat Immunol，2005， 5 (11)： 749-759.

[22] Bojana Z，Alja S，Metka F. Genotoxicity and potential carcinogenicity of cyanobacterial toxins -a review[J]. Mutat Res，2011，727(1)： 16-41.

[23] Maeda S，Kamata H，Luo JL，et al. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis[J]. Cell，2005，121(7)：977-990.

[24] Higashitsuji H，Higashitsuji A，Liu Y，et al. The oncoprotein gankyrin Interacts with RelA and suppresses NF-κB activity[J]. BBRC，2007，363(3)：879-884.

[25] Chen Y，LI HH，Fu J，et al. Oneoprotein P28GANK binds to RelA and retains NF-κB in the cytoplasm through nuclear export[J]. Cell Res，2007，17(10)：1020-1029.

[26] Kuo MT，Niramol S. Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance[J]. Mol Carcinog，2006， 45(5)：701-709.

[27] Zhang J，Yang Y. Gankyrin plays an essential role in estrogen-driven and GPR30-mediated endometrial carcinoma cell proliferation via the PTEN/PI3K/AKT signaling pathway[J]. Cancer Letters，2013， 339 (2)：279-287.

[28] Sun W，Ding J，Wu K，et al. Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of hepatocytes and hepatoma cells[J]. Hepatology，2011，54(4)：1259-1272.

[29] Dai RY，Chen Y，Fu J，et al. p28GANK inhibits endoplasmic reticulum stress-induced cell death via enhancement of the endoplasmic reticulum adaptive capacity[J]. Cell Res，2009，19(11)：1243-1257.

[30] Melissa M. Center and Ahmedin Jemal. International trends in liver cancer incidence rates[J]. Cancer Epidemiol Biomarkers Prev，2011， 20(11)：2362-2369.

[31] 陈建国，张思维，陈万青. 中国2004～2005年全国死因回顾抽样调查肝癌死亡率分析[J]. 中华预防医学杂志，2010，44(5)：383-389.

[32] Macdonald GA．Pathogenesis of hepatocellular carcinoma[J]. Clin Liver Dis，2001，5(1)：69-85.

[33] Sakurai T，He GB，Matsuzawa A，et al. Hepatocyte necrosis induced by oxidative stress and IL-1a release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis [J]. Cancer Cell， 2008，14(2)：156-165.

[34] Peng A，Maller JL. Serine/threonine phosphatases in the DNA damage response and cancer[J]. Oncogene，2010，29(45)：5977-5988.

[35] Douglas H，Robert AW. Hallmarks of cancer：The next generation[J]. Cell，2011，144(5)：646-674.